Afficher la notice abrégée

Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo

dc.rights.licenseopenen_US
dc.contributor.authorKONU, Yao Rodion
dc.contributor.authorTAKASSI, Elom
dc.contributor.authorPEYTAVIN, Gilles
dc.contributor.authorDAPAM, Nina
dc.contributor.authorDAMOND, Florence
dc.contributor.authorOUMAROU, Wone Adama
dc.contributor.authorZAIDI, Meryem
dc.contributor.authorFRANCO-YUSTI, Anna-Maria
dc.contributor.authorDAGNRA, Claver A.
dc.contributor.authorLE HINGRAT, Quentin
dc.contributor.authorCOPPEE, Romain
dc.contributor.authorDESCAMPS, Diane
dc.contributor.authorDIALLO, Fatoumata Binta Tidiane
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorEKOUEVI, Didier Koumavi
dc.contributor.authorCHARPENTIER, Charlotte
dc.date.accessioned2024-08-21T12:19:25Z
dc.date.available2024-08-21T12:19:25Z
dc.date.issued2024-05-15
dc.identifier.issn1537-6591en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201234
dc.description.abstractEnBackground. Few data are available on the real-world efficacy of receiving tenofovir-lamivudine-dolutegravir (-DTG) as human immunodeficiencyvirus (HIV) treatment, particularly among young people in West Africa. Here, we evaluated pharmaco-virological outcomes and resistance profiles among Togolese children and adolescents. Methods. A cross-sectional study was conducted in Lom & eacute;, Togo, enrolling antiretroviral-treated people with HIV aged from 18 months to 24 years. Plasma HIV-1 viral load and antiretroviral concentrations were measured. Next-generation sequencing of protease, reverse transcriptase (RT), and integrase was performed on all samples with viral loads >200 copies/mL. Drug resistance mutations (DRMs) were identified and interpreted using the ANRS-MIE algorithm. Results. 264 participants were enrolled (median age, 17 years); 226 received a DTG-based regimen for a median of 20.5 months. Among them, there was virological suppression at the 200-copies/mL threshold in 80.0% of the participants. Plasma DTG concentrations were adequate (ie, >640 ng/mL), suboptimal, and below the limit of quantification in 74.1%, 6.7%, and 19.2% of participants receiving DTG, respectively. Overall, viruses resistant to any of nucleoside RT inhibitors, non-NRTIs, and protease inhibitors were found in 52%, 66%, and 1.6% of participants, respectively. A major integrase inhibitor DRM was observed in 9.4% (n = 3/32; R263K, E138A-G140A-Q148R, and N155H) of participants with a viral load >200 copies/mL. Conclusions. These first findings in a large series of adolescents in a low-income country showed a good virological response of 80% and the presence of an integrase DRM in 9.4% of virological failures, supporting the need to monitor DTG drug resistance to reduce the risk of resistance acquisition.
dc.language.isoENen_US
dc.subject.enHIV
dc.subject.enTogo
dc.subject.enChildren/adolescents
dc.subject.enConcentrations
dc.subject.enDolutegravir
dc.subject.enResistance
dc.title.enPharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo
dc.title.alternativeClin Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/cid/ciae278en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38748464en_US
bordeaux.journalClinical Infectious Diseasesen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
bordeaux.identifier.funderIDWorld Health Organizationen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.identifierhal-04674542
hal.version1
hal.date.transferred2024-08-21T12:19:27Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Infectious%20Diseases&rft.date=2024-05-15&rft.eissn=1537-6591&rft.issn=1537-6591&rft.au=KONU,%20Yao%20Rodion&TAKASSI,%20Elom&PEYTAVIN,%20Gilles&DAPAM,%20Nina&DAMOND,%20Florence&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée